Literature DB >> 21715978

The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.

Mikhail V Blagosklonny1.   

Abstract

Suppose one drug causes lethal mitotic arrest, another treatment causes irreversible senescence and a third drug inhibits cellular mass growth: Could cells treated with a combination of all three agents magically emerge alive and proliferating? The result of this experiment is presented here. By knowing the mechanisms of cell cycle arrest, death and senescence, we can design "rainbow combinations" that obediently kill or spare desired cells. Knowledge is power.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715978     DOI: 10.4161/cc.10.14.16819

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Authors:  Neil Beeharry; Eugenia Banina; James Hittle; Natalia Skobeleva; Vladimir Khazak; Sean Deacon; Mark Andrake; Brian L Egleston; Jeffrey R Peterson; Igor Astsaturov; Timothy J Yen
Journal:  Cell Cycle       Date:  2014-06-23       Impact factor: 4.534

2.  K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway.

Authors:  Alessandro Poli; Irene Faenza; Francesca Chiarini; Alessandro Matteucci; James A McCubrey; Lucio Cocco
Journal:  Cell Cycle       Date:  2013-05-06       Impact factor: 4.534

Review 3.  Rapalogs in cancer prevention: anti-aging or anticancer?

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2012-11-14       Impact factor: 4.742

4.  Cell-cycle fate-monitoring distinguishes individual chemosensitive and chemoresistant cancer cells in drug-treated heterogeneous populations demonstrated by real-time FUCCI imaging.

Authors:  Shinji Miwa; Shuya Yano; Hiroaki Kimura; Mako Yamamoto; Makoto Toneri; Yasunori Matsumoto; Fuminari Uehara; Yukihiko Hiroshima; Takashi Murakami; Katsuhiro Hayashi; Norio Yamamoto; Michael Bouvet; Toshiyoshi Fujiwara; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.

Authors:  Meong Cheol Shin; Jian Zhang; Allan E David; Wolfgang E Trommer; Young Min Kwon; Kyoung Ah Min; Jin H Kim; Victor C Yang
Journal:  J Control Release       Date:  2013-08-23       Impact factor: 9.776

6.  Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin.

Authors:  Olga V Leontieva; Zoya N Demidenko; Andrei V Gudkov; Mikhail V Blagosklonny
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

7.  Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy.

Authors:  Robin M Hallett; Cheng Huang; Ali Motazedian; Stefanie Auf der Mauer; Gregory R Pond; John A Hassell; Robert E Nordon; Jonathan S Draper
Journal:  Oncotarget       Date:  2015-03-30

Review 8.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

Review 9.  Recent discoveries in the cycling, growing and aging of the p53 field.

Authors:  James A McCubrey; Zoya N Demidenko
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

10.  Rapamycin extends life- and health span because it slows aging.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2013-08       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.